Sarepta Gobbles Up Gene Therapy Partner Myonexus After Early Data Win In Muscular Dystrophy

 
• By Jo Shorthouse

Sarepta Therapeutics has wasted no time in buying out partner Myonexus, swallowing up five extra clinical candidates, after studies of its lead gene therapy for limb-girdle muscular dystrophy showed positive results.

Fish
Sarepta is following the money with Myonexus Buy • Source: Shutterstock

More from Deals

More from Business